早期Cenobamate作为药物耐药焦点的第三线选择:一个范式转变?
Fedele Dono1,2, Mirella Russo1, Rita Agosto1,2
1Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Via Dei Vestini 1, 6610, Chieti, Italy.
Neurology and therapy
|March 13, 2026
概括
早期的第三线赛诺巴酸 (CNB) 在耐药性中表现出优异的12个月保留时间和发作自由度,相比于佩拉曼内尔 (PER) 和布里瓦拉 (BRV). 随着CNB的使用,不良事件的频率较低,这表明了有利的现实世界有效性概况.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 耐药性 (DRE) 影响近30%的患者,抗发作药物 (ASM) 的最佳顺序不确定.
- 有限的比较现实世界的证据表明,在DRE管理中早期使用较新的ASM.
- 这项研究评估了赛诺巴 (CNB) 与佩拉曼内尔 (PER) 和布里瓦拉 (BRV) 相比,作为焦点发病的DRE的早期第三线治疗.
研究的目的:
- 为了比较现实世界中的有效性和安全性,塞诺巴 (CNB) 与佩拉曼内尔 (PER) 和布里瓦拉 (BRV) 在成年人中具有焦点发作的DRE.
- 评估与PER/BRV相比,CNB的12个月治疗保留率.
- 为了评估响应率和不良事件在3,6和12个月后启动.
主要方法:
- 多中心观察研究包括34名CNB患者和37名匹配的PER/BRV对照,所有这些患者在之前两次ASM失败后都患有DRE.
- 主要结局:持续治疗12个月. 二级结局:反应率 (≥50%,≥75%,100%的发作减少) 和不良事件.
- 使用单变量统计和纵向通用线性混合效应模型 (GLMMs) 的探索性比较分析.
主要成果:
- 雪诺巴酸 (CNB) 的12个月保留率达到了94.1%.
- 12个月的描述性发作自由度为CNB的62.5%,而PER为43.7%,BRV为16.6%.
- 与对照组 (35.3%) 相比,CNB的不良事件发生频率明显低 (9.4%),GLMM显示CNB的发作频率减少得更快.
结论:
- 与其他第三线ASM相比,早期的第三线赛诺巴 (CNB) 在现实世界DRE治疗中显示出潜在的更高的有效性和可接受的耐受性.
- 研究结果表明,CNB可能是优化焦点发作DRE治疗顺序的有价值选择.
- 需要进行更大规模的前性研究来证实这些发现,并完善DRE的治疗策略.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Potassium Channel Activators
895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
895
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Antiepileptic Drugs: Sodium Channel Blockers
2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K


